{"title":"Comparison of TEG Parameters Between Clopidogrel-resistant Resistant and Non-resistant Groups.","authors":"Adriana A Rodriguez Alvarez, Isabella Ferlini Cieri, Mounika Naidu Boya, Sasha Suarez Ferreira, Shiv Patel, Jeongin Jang, Kellie Machlus, Anahita Dua","doi":"10.1097/SLA.0000000000006771","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Compare TEG parameters between clopidogrel-resistant and clopidogrel-non-resistant groups.</p><p><strong>Summary background data: </strong>Graft or stent thrombosis affects 1 in 5 patients within six months post-revascularization and is a leading cause of amputation in the elderly. Clopidogrel resistance occurs in 5-44% of patients.</p><p><strong>Methods: </strong>This prospective observational study evaluated patients with PAD undergoing revascularization and taking clopidogrel between 2022 and 2024. Whole blood samples were analyzed using thromboelastography (TEG) and VerifyNow testing. Patients were categorized based on their clopidogrel response: clopidogrel-resistant (>180 P2Y12 Reaction Units (PRU)) and non-resistant (<180 PRU). Fisher's exact and Wilcoxon tests were used to compare the groups for categorical and continuous variables, respectively. Spearman's correlation coefficient was used to determine the relationship between platelet function and clopidogrel response (VerifyNow).</p><p><strong>Results: </strong>Fifty-three patients were analyzed, 70% were male, and 23% were clopidogrel-resistant. Clopidogrel-resistant exhibited higher platelet reactivity (PRU 224.2 vs. 74.9, P<0.0001), faster clot formation (1.14min vs. 1.22min, P<0.0001), clot strength (ADP-MA 54.9 mm vs. 39.8 mm, P<0.0001), and reduced clot lysis (0.97min vs. 0.69min, P=0.0005) compared to non-resistant. Additionally, these patients showed a higher percentage of platelet aggregation (74.0% vs. 44.0%, P<0.0001) and a lower platelet inhibition (26.0% vs. 56.0%, P<0.0001), indicating a diminished response to clopidogrel and an increased risk of thrombosis.</p><p><strong>Conclusion: </strong>Clopidogrel-resistant group exhibited faster clot formation, greater clot strength, and higher platelet aggregation. Incorporating TEG into clinical practice could help identify patients at risk of inadequate clopidogrel response.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SLA.0000000000006771","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Compare TEG parameters between clopidogrel-resistant and clopidogrel-non-resistant groups.
Summary background data: Graft or stent thrombosis affects 1 in 5 patients within six months post-revascularization and is a leading cause of amputation in the elderly. Clopidogrel resistance occurs in 5-44% of patients.
Methods: This prospective observational study evaluated patients with PAD undergoing revascularization and taking clopidogrel between 2022 and 2024. Whole blood samples were analyzed using thromboelastography (TEG) and VerifyNow testing. Patients were categorized based on their clopidogrel response: clopidogrel-resistant (>180 P2Y12 Reaction Units (PRU)) and non-resistant (<180 PRU). Fisher's exact and Wilcoxon tests were used to compare the groups for categorical and continuous variables, respectively. Spearman's correlation coefficient was used to determine the relationship between platelet function and clopidogrel response (VerifyNow).
Results: Fifty-three patients were analyzed, 70% were male, and 23% were clopidogrel-resistant. Clopidogrel-resistant exhibited higher platelet reactivity (PRU 224.2 vs. 74.9, P<0.0001), faster clot formation (1.14min vs. 1.22min, P<0.0001), clot strength (ADP-MA 54.9 mm vs. 39.8 mm, P<0.0001), and reduced clot lysis (0.97min vs. 0.69min, P=0.0005) compared to non-resistant. Additionally, these patients showed a higher percentage of platelet aggregation (74.0% vs. 44.0%, P<0.0001) and a lower platelet inhibition (26.0% vs. 56.0%, P<0.0001), indicating a diminished response to clopidogrel and an increased risk of thrombosis.
Conclusion: Clopidogrel-resistant group exhibited faster clot formation, greater clot strength, and higher platelet aggregation. Incorporating TEG into clinical practice could help identify patients at risk of inadequate clopidogrel response.
期刊介绍：
The Annals of Surgery is a renowned surgery journal, recognized globally for its extensive scholarly references. It serves as a valuable resource for the international medical community by disseminating knowledge regarding important developments in surgical science and practice. Surgeons regularly turn to the Annals of Surgery to stay updated on innovative practices and techniques. The journal also offers special editorial features such as "Advances in Surgical Technique," offering timely coverage of ongoing clinical issues. Additionally, the journal publishes monthly review articles that address the latest concerns in surgical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
